Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179930 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
A Phase 2 study of Lymphoma and Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 9
- Study locations
NCT03179930: Active Phase 2 study of Lymphoma and Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03179930 is a Phase 2 study of Lymphoma and Refractory that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03179930, a Phase 2 study of Lymphoma and Refractory, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.
Primary Outcome
will be evaluated in this study using the 2014 Lugano Classification.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Entinostat
Study Locations (9)
New York
- Roswell Park Cancer Institute (Data Collection Only) - Buffalo
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Illinois
- Northwestern University (Data Collection Only) - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT03179930 still lists
NCT03179930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03179930 lists 9 locations in 3 states (New York, New Jersey, Illinois).
Frequently Asked Questions
What is clinical trial NCT03179930 about?
NCT03179930 is a clinical study titled "Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas". The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat t...
What is the current status of trial NCT03179930?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2017-06-07. Estimated completion is 2026-06.
What conditions does trial NCT03179930 study?
This clinical trial studies the following conditions: Lymphoma, Refractory, Relapsed.
What interventions are being tested in trial NCT03179930?
The interventions under investigation include: Pembrolizumab (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT03179930?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03179930 being conducted?
This trial has 9 study locations across Illinois, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03179930's enrollment target sits among peer trials
47 160th of 299 higher than 139 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI